JP2017525343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525343A5 JP2017525343A5 JP2017501280A JP2017501280A JP2017525343A5 JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5 JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5
- Authority
- JP
- Japan
- Prior art keywords
- hil
- antigen
- binding
- nmol
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176619 | 2014-07-10 | ||
| EP14176619.6 | 2014-07-10 | ||
| PCT/IB2015/055226 WO2016005950A1 (en) | 2014-07-10 | 2015-07-10 | Immune-stimulating monoclonal antibodies against human interleukin-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525343A JP2017525343A (ja) | 2017-09-07 |
| JP2017525343A5 true JP2017525343A5 (enExample) | 2018-08-16 |
| JP7209464B2 JP7209464B2 (ja) | 2023-01-20 |
Family
ID=51162588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501280A Active JP7209464B2 (ja) | 2014-07-10 | 2015-07-10 | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894828B2 (enExample) |
| EP (2) | EP3166973B1 (enExample) |
| JP (1) | JP7209464B2 (enExample) |
| CN (1) | CN106604932B (enExample) |
| AU (1) | AU2015287227B2 (enExample) |
| CA (1) | CA2954476C (enExample) |
| DK (1) | DK3166973T3 (enExample) |
| ES (2) | ES2989669T3 (enExample) |
| WO (1) | WO2016005950A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260218B2 (en) | 2016-01-11 | 2023-04-01 | Novartis Ag | Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins |
| KR20190057113A (ko) | 2016-09-28 | 2019-05-27 | 조마 (유에스) 엘엘씨 | 인터루킨-2에 결합하는 항체 및 그 용도 |
| GB201621806D0 (en) * | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| EP3585404A4 (en) * | 2017-02-23 | 2021-04-14 | City of Hope | METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD) |
| CA3057146A1 (en) | 2017-03-23 | 2018-09-27 | The Trustees Of The University Of Pennsylvania | Anti-c5a antibodies and uses thereof |
| AU2018271751B2 (en) * | 2017-05-25 | 2021-04-01 | Institute For Basic Science | Anti-human interleukin-2 antibodies and uses thereof |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2023509991A (ja) | 2020-01-13 | 2023-03-10 | シンアフィックス ビー．ブイ． | 抗体及び免疫細胞エンゲージャーのコンジュゲート |
| CN115397852B (zh) | 2020-02-16 | 2023-08-11 | 奥罗斯生物科学公司 | 工程化抗il-2抗体 |
| CA3189257A1 (en) * | 2020-08-18 | 2022-02-24 | Universitat Zurich | A cd25-biased anti-il-2 antibody |
| CN117157107A (zh) | 2021-02-08 | 2023-12-01 | 西纳福克斯股份有限公司 | 多功能抗体 |
| CA3234995A1 (en) | 2021-10-14 | 2023-04-20 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
| CN119912559B (zh) * | 2025-01-22 | 2025-12-26 | 贵州中医药大学 | 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用 |
| CN119775409B (zh) * | 2025-03-05 | 2025-07-11 | 深圳真实生物医药科技有限公司 | 靶向sost的抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK174501B1 (da) | 1983-12-23 | 2003-04-28 | Hoffmann La Roche | Fremgangsmåde til fremstilling af interleukin-2 |
| DK134487A (da) * | 1986-03-17 | 1987-09-18 | Hoffmann La Roche | Monoklonalt antistof med affinitet for humant interleukin-2 |
| DK0920505T3 (da) | 1996-08-16 | 2008-09-08 | Schering Corp | Pattedyrcelleoverfladeantigener og tilhörende reagenser |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| EP1578419A4 (en) | 2002-12-30 | 2008-11-12 | 3M Innovative Properties Co | IMMUNOSTIMULATING COMBINATIONS |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| EP1888644A1 (en) | 2005-06-01 | 2008-02-20 | Micromet AG | Anti-il2 antibodies |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| US20100310501A1 (en) * | 2006-02-16 | 2010-12-09 | Onur Boyman | Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject |
| CN101045923B (zh) * | 2006-03-31 | 2011-11-23 | 沈阳三生制药有限责任公司 | 生产一种白细胞介素类似物的方法 |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| ME03661B (me) | 2010-08-12 | 2020-07-20 | Lilly Co Eli | Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba |
| TWI666027B (zh) | 2011-02-10 | 2019-07-21 | 羅齊克雷雅公司 | 突變介白素-２多肽 |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
-
2015
- 2015-07-10 DK DK15759938.2T patent/DK3166973T3/da active
- 2015-07-10 ES ES20158066T patent/ES2989669T3/es active Active
- 2015-07-10 AU AU2015287227A patent/AU2015287227B2/en not_active Ceased
- 2015-07-10 CN CN201580048027.0A patent/CN106604932B/zh active Active
- 2015-07-10 JP JP2017501280A patent/JP7209464B2/ja active Active
- 2015-07-10 EP EP15759938.2A patent/EP3166973B1/en active Active
- 2015-07-10 EP EP20158066.9A patent/EP3693389B1/en active Active
- 2015-07-10 WO PCT/IB2015/055226 patent/WO2016005950A1/en not_active Ceased
- 2015-07-10 US US15/324,468 patent/US10894828B2/en active Active
- 2015-07-10 ES ES15759938T patent/ES2779977T3/es active Active
- 2015-07-10 CA CA2954476A patent/CA2954476C/en active Active
-
2020
- 2020-12-22 US US17/131,221 patent/US20210230269A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525343A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
| JP2020500538A5 (enExample) | ||
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| MY198942A (en) | Anti-tau antibodies and methods of use | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| JP2017505125A5 (enExample) | ||
| RU2014108309A (ru) | Антиполиубиквитиновые антитела и способы применения | |
| JP2020537520A5 (enExample) | ||
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| JP2016520595A5 (enExample) | ||
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| JP2017521054A5 (enExample) | ||
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
| RU2016143552A (ru) | Гуманизированные антитела к антигену Томсена-Фриденрайха | |
| RU2016129166A (ru) | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии | |
| JP2017511152A5 (enExample) |